DNA damage repair in ovarian cancer: unlocking the heterogeneity
Abstract Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments and better patient selection. Abrogations in the DNA damag...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2018-06-01
|
| Series: | Journal of Ovarian Research |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s13048-018-0424-x |
| _version_ | 1797970104905891840 |
|---|---|
| author | Mary Ellen Gee Zahra Faraahi Aiste McCormick Richard J. Edmondson |
| author_facet | Mary Ellen Gee Zahra Faraahi Aiste McCormick Richard J. Edmondson |
| author_sort | Mary Ellen Gee |
| collection | DOAJ |
| description | Abstract Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments and better patient selection. Abrogations in the DNA damage response (DDR) may allow such stratifications. A defective DNA-damage response (DDR) is a defining hallmark of high grade serous ovarian cancer (HGSOC). Indeed, current evidence indicates that all HGSOCs harbour a defect in at least one major DDR pathway. However, defective DDR is not mediated through a single mechanism but rather results from a variety of (epi)genetic lesions affecting one or more of the five major DNA repair pathways. Understanding the relationship between these pathways and how these are abrogated will be necessary in order to facilitate appropriate selection of both existing and novel agents. Here we review the current understanding of the DDR with regard to ovarian, and particularly high grade serous, cancer, with reference to existing and emerging treatments as appropriate. |
| first_indexed | 2024-04-11T03:12:47Z |
| format | Article |
| id | doaj.art-78e3258089e64e5eb302595cdd84df5b |
| institution | Directory Open Access Journal |
| issn | 1757-2215 |
| language | English |
| last_indexed | 2024-04-11T03:12:47Z |
| publishDate | 2018-06-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Ovarian Research |
| spelling | doaj.art-78e3258089e64e5eb302595cdd84df5b2023-01-02T11:17:54ZengBMCJournal of Ovarian Research1757-22152018-06-0111111210.1186/s13048-018-0424-xDNA damage repair in ovarian cancer: unlocking the heterogeneityMary Ellen Gee0Zahra Faraahi1Aiste McCormick2Richard J. Edmondson3Division of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary’s HospitalDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary’s HospitalNorthern Institute for Cancer Research, Newcastle University, Framlington PlaceDivision of Cancer Sciences, Faculty of Biology, Medicine and Health, University of Manchester, St Mary’s HospitalAbstract Treatment for advanced ovarian cancer is rarely curative; three quarters of patients with advanced disease relapse and ultimately die with resistant disease. Improving patient outcomes will require the introduction of new treatments and better patient selection. Abrogations in the DNA damage response (DDR) may allow such stratifications. A defective DNA-damage response (DDR) is a defining hallmark of high grade serous ovarian cancer (HGSOC). Indeed, current evidence indicates that all HGSOCs harbour a defect in at least one major DDR pathway. However, defective DDR is not mediated through a single mechanism but rather results from a variety of (epi)genetic lesions affecting one or more of the five major DNA repair pathways. Understanding the relationship between these pathways and how these are abrogated will be necessary in order to facilitate appropriate selection of both existing and novel agents. Here we review the current understanding of the DDR with regard to ovarian, and particularly high grade serous, cancer, with reference to existing and emerging treatments as appropriate.http://link.springer.com/article/10.1186/s13048-018-0424-xNon-homologous end joiningHomologous recombinationNucleotide excision repairBase excision repairMismatch repairOvarian cancer |
| spellingShingle | Mary Ellen Gee Zahra Faraahi Aiste McCormick Richard J. Edmondson DNA damage repair in ovarian cancer: unlocking the heterogeneity Journal of Ovarian Research Non-homologous end joining Homologous recombination Nucleotide excision repair Base excision repair Mismatch repair Ovarian cancer |
| title | DNA damage repair in ovarian cancer: unlocking the heterogeneity |
| title_full | DNA damage repair in ovarian cancer: unlocking the heterogeneity |
| title_fullStr | DNA damage repair in ovarian cancer: unlocking the heterogeneity |
| title_full_unstemmed | DNA damage repair in ovarian cancer: unlocking the heterogeneity |
| title_short | DNA damage repair in ovarian cancer: unlocking the heterogeneity |
| title_sort | dna damage repair in ovarian cancer unlocking the heterogeneity |
| topic | Non-homologous end joining Homologous recombination Nucleotide excision repair Base excision repair Mismatch repair Ovarian cancer |
| url | http://link.springer.com/article/10.1186/s13048-018-0424-x |
| work_keys_str_mv | AT maryellengee dnadamagerepairinovariancancerunlockingtheheterogeneity AT zahrafaraahi dnadamagerepairinovariancancerunlockingtheheterogeneity AT aistemccormick dnadamagerepairinovariancancerunlockingtheheterogeneity AT richardjedmondson dnadamagerepairinovariancancerunlockingtheheterogeneity |